http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014013338-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0704202bcaa7f6fec4e7cae102a34838 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate | 2013-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d920cd231b693b1c7d08fe0bcb9575f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52eb7eb0fdb7526ed85d93ebc9b9939a |
| publicationDate | 2014-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2014013338-A3 |
| titleOfInvention | Compounds for the treatment of alzheimer's disease |
| abstract | The present invention relates to the use of compounds of formula (I): wherein R 1 is H, substituted or unsubstituted aryl, heteroaryl or C 1-24 aliphatic group, -(CH 2 ) 1-3 -aryl or -(CH 2 ) 1-3 - heteroaryl, R 2 is selected from the group consisting of H, substituted or unsubstituted aryl, heteroaryl or C 1-24 aliphatic group, -OR a , halo, N(R a )(R b ), N 3 , -(CH 2 ) 1-3 Ra and -(CH 2 ) 1-3 -halo, wherein R a n and R b are independently selected from the group consisting of H, C 1-3 alkyl, aryl or heteroaryl, or R a and R b are taken together with the atom to which they are attached to form a 3 to 6 membered ring and wherein at least one of R 1 and R 2 is not H to provide neuroprotection via a GABA A -dependent or GABA A -indedependent pathway wherein the compound acts in a neuroprotective and/or neurorestorative manner with reduced sedative effects. In an alternate embodiment, the invention relates to the use of GT-1061 for upregulating or activating NO/cGMP/CREB pathway to provide neuroprotective and neurorestorative effects, to lower the levels of Αβ protein in the brain or to lower the level of tau, without causing sedation, hi another embodiment, the invention relates to the use of GT-1061 to treat a neurodegenerative disease or Alzheimer's disease or related disorders without causing sedative effects. |
| priorityDate | 2012-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.